These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results Terminated 2004-000361-35 A 12-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON'S DISEASE WITH "WEARING OFF" MOTOR FLUCTUATIONS AND... 2008-04-10 due-trials
Reported results 2004-000774-31 An open-label, randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer... 2006-09-21 due-trials
Reported results 2004-001162-40 An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognit... 2006-10-20 due-trials
Completed, but no date, and reported results 2004-002597-33 An open label dose adjustment and phase II study of E7070 in combination with capecitabine: Part 1: to determine the recommended dose of the combination Part 2: to determine the efficacy of the comb... bad-data
Completed, but no date, and reported results 2004-003355-39 A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia. bad-data
Reported results 2005-000260-57 Randomized trial to assess efficacy and safety of an add-on treatment with zonisamide in adults with focal epileptic seizures with or without secondary generalization 2008-02-27 due-trials
Reported results 2005-001982-33 An Open Label Study of ZONEGRANTM Zonisamide in patients with partial onset seizures 2007-08-03 due-trials
Reported results 2005-003656-35 A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to th... 2009-10-15 due-trials
Reported results 2005-004009-26 A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines ... 2018-01-16 due-trials
Reported results 2005-004199-18 A Double-blind, Placebo-controlled, Dose-escalation, Parallel Group Study of E2007 given as Adjunctive Therapy in Patients with Refractory Partial Seizures 2007-02-06 due-trials
Reported results 2005-004271-37 A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy... 2010-02-18 due-trials
Reported results 2005-004272-20 Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma 2012-06-28 due-trials
Reported results 2005-004293-24 A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 as an Adjunctive Therapy in Patients With Refractory Partial Seizures 2014-07-01 due-trials
Reported results 2005-004314-33 A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctua... 2007-08-23 due-trials
Reported results 2005-004503-11 Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute M... 2013-05-27 due-trials
Reported results 2005-005537-35 A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis 2010-10-28 due-trials
Reported results 2005-006029-94 A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease 2009-08-14 due-trials
Reported results 2006-000156-40 "Estudio aleatorizado, multicéntrico, doble ciego, para comparar la eficacia y seguridad de zonisamida y carbamazepina como monoterapia en pacientes con epilepsia parcial recién diagnosticada" (A ran... 2011-01-14 due-trials
Reported results 2006-000296-15 A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary... 2009-06-09 due-trials
Reported results 2006-001949-34 A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician's Choice' in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously Tr... 2013-05-31 due-trials
Reported results 2006-002339-26 A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Flu... 2008-07-30 due-trials
Reported results 2006-002515-27 A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizures 2011-03-15 due-trials
Reported results 2006-002516-10 A randomised, double blind, placebo-controlled study to evaluate the safety and tolerability and to explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial sei... 2010-11-23 due-trials
Reported results 2006-002937-20 A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients wi... 2008-06-18 due-trials
Reported results 2006-003702-26 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients with Refractory Partial Seizures 2008-01-15 due-trials
Reported results 2006-004888-54 Double-Blind, Parallel-Group Comparison of 23 mg Donepezil SR to 10 mg Donepezil IR in Patients with Moderate to Severe Alzheimer’s disease 2009-03-27 due-trials
Reported results 2006-004890-93 E2020-G000-328 Estudio de extensión abierto de donepezilo LP 23 mg en pacientes con enfermedad de Alzheimer moderada o grave. Open-Label Extension Study of 23 mg Donepezil SR in Patients with Mode... 2010-04-01 due-trials
Reported results 2006-006488-22 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients with Painful Diabetic Neuropathy 2008-07-11 due-trials
Reported results 2007-000198-53 An open-label extension study following a double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizur... 2012-03-08 due-trials
Reported results 2007-000801-30 A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Flu... 2008-06-27 due-trials
Reported results 2007-003556-10 A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy. 2009-01-05 due-trials
Reported results 2007-003557-91 A double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizures 2009-01-28 due-trials
Reported results 2007-005313-19 A multicentre, randomised, active comparator, parallel group study to compare the effect on cognition of adjunctive therapy with zonisamide versus sodium valproate. 2008-12-08 due-trials
Reported results 2007-005435-28 Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment 2009-09-18 due-trials
Reported results 2007-005442-20 Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment 2009-05-22 due-trials
Reported results 2007-005495-13 A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients with Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neural... 2009-11-12 due-trials
Reported results 2007-005570-32 A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas... 2009-09-14 due-trials
Reported results 2007-005933-12 Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified b... 2019-02-18 due-trials
Reported results 2007-006046-17 A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas... 2009-09-10 due-trials
Reported results 2007-006168-31 A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel- Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial ... 2011-02-12 due-trials
Reported results 2007-006169-33 A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel- Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Sei... 2010-06-09 due-trials
Reported results 2007-006170-28 A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo- Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive T... 2014-09-18 due-trials
Trial is outside EEC, and reported results 2007-006191-11 A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seiz... bad-data
Completed, but no date Terminated 2007-006695-10 Open Label Extension Study Following Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Adjunctive Zonisamide in Primary Generalized Tonic-Clonic Seizures bad-data
Completed, but no date Terminated 2007-006696-36 Open label Extension Study Following Double-blind, Randomized, Placebo-controlled, Multicentre Study to Assess Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures associated with Idiopa... bad-data
Reported results 2008-001159-23 A Randomized, Double-Blind Extension Study to Assess the Long-Term Safety and to Explore the Long-Term Efficacy of Zonisamide as Monotherapy in Newly Diagnosed Partial Seizures 2011-07-26 due-trials
Reported results 2008-002843-18 A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor... 2013-01-10 due-trials
Reported results 2008-005236-32 Dalteparin Sodium Injection (Fragmin®), Multicenter, Open Label, Single-arm, Long Term (52 weeks) Study for Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Throm... 2012-03-15 due-trials
Reported results 2008-005872-29 A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum... 2013-01-25 due-trials
Completed, but no date, and reported results 2009-010895-64 A superiority, randomized, open-label, multi-center study to compare the efficacy and safety of adjunctive zonisamide vs replacement with zonisamide of the last added antiepileptic drug in patients wi... bad-data
Exempt, with results 2009-011217-24 A Phase 1b/2, Multicenter, Open-label, Dose-escalation and Confirmation Study of Eribulin in Combination with Capecitabine 2015-10-13 not-yet-due
Reported results 2009-014815-11 A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects with Psoriasis Vulgaris 2010-12-11 due-trials
Exempt, with results 2009-016047-19 An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination with Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients with Advanced Non-S... 2015-05-18 not-yet-due
Exempt, with results Terminated 2009-016050-41 An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Platinum... not-yet-due
Reported results 2009-016858-41 An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy 2015-10-10 due-trials
Completed, but no date, and reported results 2009-017671-22 An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies bad-data
Reported results 2010-018518-56 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pha... 2014-09-01 due-trials
Exempt, with results 2010-019484-10 An open-label, multicenter Phase Ib/2 study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-target... 2018-02-08 not-yet-due
Reported results 2010-019526-14 An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma 2014-12-01 due-trials
Exempt Terminated 2010-020204-30 A Multicenter, Open-label, Sequential, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy or Eritoran in Descending Age Groups of Pediatric Subj... 2011-02-09 not-yet-due
Trial is partly outside EEC, and reported results 2010-023505-36 A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to ... 2015-11-02 bad-data
Reported results 2010-023783-41 A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I- Refractory Differentiated Thyroid Cancer Studio di Fase 3, multicentrico, randomizzato, in doppio ciec... 2019-03-14 due-trials
Reported results 2010-024479-20 A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, with an Open-Label Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects wit... 2014-06-27 due-trials
Reported results 2010-024483-17 A Randomised, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma. 2016-08-10 due-trials
Reported results 2011-000265-12 A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized... 2015-10-16 due-trials
Reported results 2011-000724-15 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell Lung Cancer. Studio... 2016-05-02 due-trials
Reported results 2011-000752-41 An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Sorafenib versus Sorafenib Alone as First Line Therapy in Patients with Hepatocellular Carcinoma 2015-06-30 due-trials
Exempt, with results 2011-000773-31 An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cetuximab versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and N... 2017-09-04 not-yet-due
Exempt, with results Terminated 2011-000774-58 An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cisplatin and Capecitabine versus Cisplatin and Capecitabine Alone in Patients with Advanced or Metastatic Solid ... 2012-06-07 not-yet-due
Reported results 2011-000830-12 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care fo... 2015-04-09 due-trials
Reported results Terminated 2011-000831-10 A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 versus Eltrombopag, in Ad... 2013-01-22 due-trials
Trial is outside EEC, and reported results 2011-001105-28 An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as a... bad-data
Exempt, with results 2011-001959-37 An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combination... 2015-07-14 not-yet-due
Reported results 2011-002347-10 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) versus BSC Alone in Patients with Locally Advanced or Metastatic Non-Squamous Non... 2015-06-27 due-trials
Ongoing 2012-002843-11 A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Earl... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-002992-33 A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carc... 2021-03-10 bad-data
Reported results 2013-000324-34 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Long-Term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events ... 2018-04-23 due-trials
Reported results 2013-000934-36 A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Assoc... 2017-01-30 due-trials
Reported results 2013-000965-34 A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Assoc... 2017-01-26 due-trials
Completed, but no date, and reported results 2013-005391-17 An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 years of ... bad-data
Trial is partly outside EEC, and reported results 2013-005534-38 Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies 2022-07-20 bad-data
Trial is partly outside EEC, and reported results 2014-002167-16 An Open-Label, Multicenter Study with an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension when Administered as an Adjunctive Ther... 2021-12-06 bad-data
Reported results 2014-002321-35 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 years of Age With Inadequately Control... 2021-07-19 due-trials
Reported results 2014-003812-36 A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylate... 2020-08-13 due-trials
Reported results 2014-005199-27 A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will... 2020-09-08 due-trials
Reported results 2015-001463-39 A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel-Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder 2019-01-08 due-trials
Completed, but no date, and reported results Terminated 2015-001929-17 This is an Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC). Sperimentazione multicentrica di fase 2, in aperto, a braccio singo... bad-data
Reported results 2015-004347-39 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older with Insomnia Disorder 2018-01-30 due-trials
Listed as ongoing, but also has a completion date 2016-000916-14 A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of ... 2023-05-02 bad-data
Trial is outside EEC, and reported results 2016-001878-15 Single and Multiple Dose Pharmacokinetics and Safety Study of Rabeprazole Sodium in 12 to 16 Year Old Subjects bad-data
Trial is outside EEC, and reported results 2016-001879-73 Safety and Efficacy of Rabeprazole in the Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients bad-data
Trial is outside EEC, and reported results 2016-001894-34 A Phase 1 Study of Eribulin Mesylate (E7389, IND #116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lympho... bad-data
Trial is outside EEC, and reported results 2016-001896-63 An Ascending Bioavailability of a New Oral Suspension of E3810 bad-data
Listed as ongoing, but also has a completion date 2016-002778-11 A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcin... 2024-06-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2016-003352-67 A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors 2021-05-17 bad-data
Reported results 2016-003928-23 A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease 2020-01-15 due-trials
Reported results 2016-004128-42 A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease Studio di 24 mesi controllato verso placeb... 2020-01-14 due-trials
Trial is outside EEC, and reported results 2016-004944-12 A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures bad-data
Trial is outside EEC, and reported results 2016-004945-10 An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects bad-data
Trial is outside EEC, and reported results 2016-004946-27 A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down... bad-data
Trial is outside EEC, and reported results 2016-004947-35 An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A... bad-data
Trial is outside EEC, and reported results 2016-004948-11 A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down... bad-data
Trial is outside EEC, and reported results 2016-004949-92 A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down... bad-data
Trial is outside EEC, and reported results 2016-004950-14 An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures bad-data
Trial is outside EEC 2016-004951-55 A Multicenter, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures bad-data
Trial is outside EEC, and reported results 2016-004952-30 A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients bad-data
Trial is outside EEC, and reported results 2016-004953-34 A Long Term Extension Study of E2080 in Patients with Lennox-Gastaut Syndrome bad-data
Trial is outside EEC 2016-004954-13 A Multi-center, Randomized, Open-label, Parallel-group, Dose-titration, Add-on, Comparative Study in Evaluating the Efficacy and Safety of Zonisamide (Zonegran) and Lamotrigine (Lamictal) for Subjects... bad-data
Trial is outside EEC 2016-004955-64 A Multicenter Comparative Trial of Zonisamide and Topiramate as Monotherapy in Epilepsy Patients: Safety for cognitive function bad-data
Trial is outside EEC 2016-004956-32 A Multi-center Comparative Trial of Low and High Dose Zonisamide in Children with Newly Diagnosed Epilepsy as Monotherapy bad-data
Trial is outside EEC, and reported results 2016-004957-33 Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation bad-data
Trial is outside EEC 2016-004958-14 A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy bad-data
Exempt, with results 2017-000300-26 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors 2022-07-25 not-yet-due
Trial is outside EEC, and reported results 2017-001180-20 Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generaliz... bad-data
Reported results 2017-003306-40 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm... 2020-04-17 due-trials
Completed, report not yet due 2017-003668-11 An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored le... 2023-12-21 not-yet-due
Reported results 2017-003728-64 A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies 2020-04-20 due-trials
Ongoing 2017-004387-35 A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Adva... not-yet-due
Trial is outside EEC, and reported results 2018-001282-17 A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft... bad-data
Trial is outside EEC, and reported results 2018-003426-89 A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled A... bad-data
Ongoing 2018-004456-38 An Open-Label Study with Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhoo... not-yet-due
Other 2018-004739-58 A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease Studio di ... not-yet-due
Exempt 2019-003600-12 A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selecte... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2019-003696-19 A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescen... 2023-08-17 bad-data
Trial is outside EEC, and reported results 2019-003734-17 A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients with Partial Onset Seizures (Including Second... bad-data
Trial is outside EEC, and reported results 2020-002109-24 A Double-blind, Placebo-controlled, Parallel-group Study With an Openlabel Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects W... bad-data
Completed, but no date 2020-004244-28 AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study with an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclin... bad-data
Exempt 2021-001568-10 An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors Estudio abierto, multicéntrico, de fase 1b/2 con E7... not-yet-due
Trial is outside EEC, and reported results 2021-006003-15 Post-Marketing Surveillance of Fycompa in Korean Patients bad-data
Trial is outside EEC 2021-006398-41 A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan bad-data
Trial is outside EEC, and reported results 2022-003736-77 A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors bad-data

Related organisations

Over time organisations can merge, or split.

We think Eisai Inc. is now also responsible for the trials of: